Epidemiology of Bladder Cancer

Kalyan Saginala, Adam Barsouk, John Sukumar Aluru, Prashanth Rawla, Sandeep Anand Padala, Alexander Barsouk, Kalyan Saginala, Adam Barsouk, John Sukumar Aluru, Prashanth Rawla, Sandeep Anand Padala, Alexander Barsouk

Abstract

Based on the latest GLOBOCAN data, bladder cancer accounts for 3% of global cancer diagnoses and is especially prevalent in the developed world. In the United States, bladder cancer is the sixth most incident neoplasm. A total of 90% of bladder cancer diagnoses are made in those 55 years of age and older, and the disease is four times more common in men than women. While the average 5-year survival in the US is 77%, the 5-year survival for those with metastatic disease is a measly 5%. The strongest risk factor for bladder cancer is tobacco smoking, which accounts for 50-65% of all cases. Occupational or environmental toxins likewise greatly contribute to disease burden (accounting for an estimated 20% of all cases), though the precise proportion can be obscured by the fact bladder cancer develops decades after exposure, even if the exposure only lasted several years. Schistosomiasis infection is the common cause of bladder cancer in regions of Africa and the Middle East and is considered the second most onerous tropical pathogen after malaria. With 81% of cases attributable to known risk factors (and only 7% to heritable mutations), bladder cancer is a prime candidate for prevention strategies. Smoking cessation, workplace safety practices, weight loss, exercise and schistosomiasis prevention (via water disinfection and mass drug administration) have all been shown to significantly decrease the risk of bladder cancer, which poses a growing burden around the world.

Keywords: bladder cancer; epidemiology; incidence; mortality; prevalence; prevention; risk factors.

Conflict of interest statement

Alexander Barsouk served as a consultant for Bristol-Myers Squibb. The other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Bar chart showing estimated age-standardized incidence and mortality rates (world) in 2018, bladder cancer, all sexes, all ages. Data obtained from Globocan 2018 [2].
Figure 2
Figure 2
Map showing estimated age-standardized incidence rates (ASR) for bladder cancer worldwide in 2018, all sexes, including all ages. Created with mapchart.net. Data obtained from Globocan 2018 [2].
Figure 3
Figure 3
Map showing estimated age-standardized mortality rates (ASR) for bladder cancer worldwide in 2018, all sexes, including all ages. Created with mapchart.net. Data obtained from Globocan 2018 [2].
Figure 4
Figure 4
Urinary Bladder (Invasive & In Situ) Cancer 5-Year SEER Relative Survival Rates, 2009–2015 By Stage at Diagnosis and Sex. Data source: US Mortality Files, National Center for Health Statistics, CDC [13].

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; Lyon, France: 2018. [(accessed on 10 January 2020)]. Available online:
    1. Andersson K.-E., Arner A. Urinary Bladder Contraction and Relaxation: Physiology and Pathophysiology. Physiol. Rev. 2004;84:935–986. doi: 10.1152/physrev.00038.2003.
    1. Mushtaq J., Thurairaja R., Nair R. Bladder Cancer. Surgery. 2019;37:529–537. doi: 10.1016/j.mpsur.2019.07.003.
    1. Mostafa M.H., Sheweita S., O’Connor P.J. Relationship between Schistosomiasis and Bladder Cancer. Clin. Microbiol. Rev. 1999;12:97–111. doi: 10.1128/CMR.12.1.97.
    1. Wong M.C., Fung F.D.H., Leung C., Cheung W.W.L., Goggins W.B., Ng A.C.F. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci. Rep. 2018;8:1129. doi: 10.1038/s41598-018-19199-z.
    1. Jamal A., Phillips E., Gentzke A.S., Homa D.M., Babb S.D., King B.A., Neff L.J. Current cigarette smoking among adults—United States, 2016. MMWR Morb. Mortal. Wkly. Rep. 2018;67:53–59. doi: 10.15585/mmwr.mm6702a1.
    1. Freedman N.D., Silverman D.T., Hollenbeck A.R., Schatzkin A., Abnet C.C. Association Between Smoking and Risk of Bladder Cancer Among Men and Women. JAMA. 2011;306:737–745. doi: 10.1001/jama.2011.1142.
    1. Al-Zalabani A., Stewart K., Wesselius A., Schols A.M.W.J., Zeegers M. Modifiable risk factors for the prevention of bladder cancer: A systematic review of meta-analyses. Eur. J. Epidemiol. 2016;31:811–851. doi: 10.1007/s10654-016-0138-6.
    1. SEER . In: SEER Cancer Statistics Review 1975–2015. Noone A.M., Howlader N., Krapcho M., Miller D., Brest A., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., et al., editors. National Cancer Institute; Bethesda, MD, USA: 2018.
    1. Silverman D.T., Koutros S., Figueroa J.D., Prokunina-Olsson L., Rothman N. Bladder cancer. In: Thun M.J., Linet M.S., Cerhan J.R., Haiman C.A., Schottenfeld D.E., editors. Cancer Epidemiology and Prevention. Oxford University Press; Oxford, UK: 2017.
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551.
    1. SEER*Explorer. [(accessed on 13 January 2020)]; Available online:
    1. Zaghloul M.S. Bladder cancer and schistosomiasis. J. Egypt. Natl. Cancer Inst. 2012;24:151–159. doi: 10.1016/j.jnci.2012.08.002.
    1. WHO WHO global report: Mortality attributable to tobacco. [(accessed on 5 January 2020)]; Available online:
    1. Hinotsu S., Akaza H., Miki T., Fujimoto H., Shinohara N., Kikuchi E., Mizutani Y., Koga H., Okajima E., Okuyama A., et al. Bladder cancer develops 6 years earlier in current smokers: Analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int. J. Urol. 2008;16:64–69. doi: 10.1111/j.1442-2042.2008.02194.x.
    1. Linn J.F., Sesterhenn I., Mostofi F.K., Schoenberg M. THE MOLECULAR CHARACTERISTICS OF BLADDER CANCER IN YOUNG PATIENTS. J. Urol. 1998;159:1493–1496. doi: 10.1097/00005392-199805000-00022.
    1. Gu J., Wu X. Genetic susceptibility to bladder cancer risk and outcome. Pers. Med. 2011;8:365–374. doi: 10.2217/pme.11.15.
    1. Kiemeney L.A., Thorlacius S., Sulem P., Geller F., Aben K.K., Stacey S.N., Gudmundsson J., Jakobsdottir M., Bergthorsson J.T., Sigurdsson A., et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet. 2008;40:1307–1312. doi: 10.1038/ng.229.
    1. Wu X., Hildebrandt M.A.T., Chang D.W. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev. 2009;28:269–280. doi: 10.1007/s10555-009-9190-y.
    1. Hein D.W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. Mol. Mech. Mutagen. 2002;506:65–77. doi: 10.1016/S0027-5107(02)00153-7.
    1. Garcia-Closas M., Malats N., Silverman D., Dosemeci M., Kogevinas M., Hein D.W., Tardon A., Serra C., Carrato A., García-Closas R., et al. NAT2 slow acetylation and GSTM1 null genotypes increase bladder cancer risk: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366:649–659. doi: 10.1016/S0140-6736(05)67137-1.
    1. Gu J., Liang N., Wang Y., Lu C., Wu X. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat. Res. Toxicol. Environ. Mutagen. 2005;581:97–104. doi: 10.1016/j.mrgentox.2004.11.012.
    1. Rothman N., Garcia-Closas M., Chatterjee N., Malats N., Wu X., Figueroa J.D., Real F.X., Berg D.V.D., Matullo G., Baris D., et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat. Genet. 2010;42:978–984. doi: 10.1038/ng.687.
    1. Riegert-Johnson D., Gleeson F., E Roberts M., Tholen K., Youngborg L., Bullock M., Boardman L.A. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered. Cancer Clin. Pr. 2010;8:6. doi: 10.1186/1897-4287-8-6.
    1. Van Der Post R.S., Kiemeney L.A., Ligtenberg M.J.L., Witjes J.A., De Kaa C.A.H.-V., Bodmer D., Schaap L., Kets C.M., Van Krieken J.H.J.M., Hoogerbrugge N. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J. Med Genet. 2010;47:464–470. doi: 10.1136/jmg.2010.076992.
    1. Phelan A., Lopez-Beltran A., Montironi R., Zhang S., Raspollini M.R., Cheng M., Kaimakliotis H.Z., O Koch M., Cheng L. Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. Future Oncol. 2018;14:277–290. doi: 10.2217/fon-2017-0346.
    1. Casadei C., Dizman N., Schepisi G., Cursano M.C., Basso U., Santini D., Pal S.K., De Giorgi U. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther. Adv. Med Oncol. 2019;11 doi: 10.1177/1758835919890285.
    1. Esrig D., Elmajian D., Groshen S., Freeman J.A., Stein J.P., Chen S.-C., Nichols P.W., Skinner D.G., Jones P.A., Cote R.J. Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer. N. Engl. J. Med. 1994;331:1259–1264. doi: 10.1056/NEJM199411103311903.
    1. Malats N., Bustos-Moreno A., Murta-Nascimento C., Fernandez F., Rivas M., Puente D., Kogevinas M., Real F.X. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6:678–686. doi: 10.1016/S1470-2045(05)70315-6.
    1. Centers for Disease Control and Prevention (US) National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health (US) How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Center for Disease Control, and Prevention; Atlanta, GE, USA: 2010.
    1. Burger M., Catto J.W., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., Kassouf W., Kiemeney L.A., La Vecchia C., Shariat S., et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer. Eur. Urol. 2013;63:234–241. doi: 10.1016/j.eururo.2012.07.033.
    1. Zeegers M.P., Kellen E., Buntinx F., van den Brandt P.A. The association between smoking, beverage consumption, diet and bladder cancer: A systematic literature review. World J. Urol. 2004;21:392–401. doi: 10.1007/s00345-003-0382-8.
    1. Yan H., Ying Y., Xie H., Li J., Wang X., He L., Jin K., Tang J., Xu X., Zheng X. Secondhand smoking increases bladder cancer risk in nonsmoking population: A meta-analysis. Cancer Manag. Res. 2018 doi: 10.2147/CMAR.S175062.
    1. Zeegers M., Swaen G.M.H., Kant I., Goldbohm R., Brandt P.A.V.D. Occupational risk factors for male bladder cancer: results from a population-based case cohort study in the Netherlands. Occup. Environ. Med. 2001;58:590–596. doi: 10.1136/oem.58.9.590.
    1. Golka K., Wiese A., Assennato G., Bolt H.M. Occupational exposure and urological cancer. World J. Urol. 2004;21:382–391. doi: 10.1007/s00345-003-0377-5.
    1. Chen H.I., Liou S.H., Loh C.H., Uang S.N., Yu Y.C., Shih T.S. Bladder cancer screening and monitoring of 4,4′-methylenebis(2-chloroaniline) exposure among workers in Taiwan. Urology. 2005;66:305–310. doi: 10.1016/j.urology.2005.02.031.
    1. Marshall G., Ferreccio C., Yuan Y., Bates M.N., Steinmaus C., Selvin S., Liaw J., Smith A.H. Fifty-Year Study of Lung and Bladder Cancer Mortality in Chile Related to Arsenic in Drinking Water. J. Natl. Cancer Inst. 2007;99:920–928. doi: 10.1093/jnci/djm004.
    1. Kurttio P., Pukkala E., Kahelin H., Auvinen A., Pekkanen J. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ. Health Perspect. 1999;107:705–710. doi: 10.1289/ehp.99107705.
    1. Meliker J.R., Nriagu J.O. Arsenic in drinking water and bladder cancer: Review of epidemiological evidence. Trace Met. other Contam. Environ. 2007;9:551–584.
    1. Zeegers M., Volovics A., Dorant E., Goldbohm R.A., Brandt P.A.V.D. Alcohol Consumption and Bladder Cancer Risk: Results from the Netherlands Cohort Study. Am. J. Epidemiol. 2001;153:38–41. doi: 10.1093/aje/153.1.38.
    1. Bagnardi V., Blangiardo M., La Vecchia C., Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br. J. Cancer. 2001;85:1700–1705. doi: 10.1054/bjoc.2001.2140.
    1. Wang C., Jiang H. Meat intake and risk of bladder cancer: A meta-analysis. Med. Oncol. 2011;29:848–855. doi: 10.1007/s12032-011-9985-x.
    1. Fei L., Wan-Long T. Red and Processed Meat Intake and Risk of Bladder Cancer: A Meta-Analysis. Ann. Oncol. 2014;25:iv489. doi: 10.1093/annonc/mdu353.14.
    1. Bertram J., Craig A. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur. J. Cancer (1965) 1972;8:587–594. doi: 10.1016/0014-2964(72)90137-5.
    1. Adeyeye S.A.O. Heterocyclic Amines and Polycyclic Aromatic Hydrocarbons in Cooked Meat Products: A Review. Polycycl. Aromat. Compd. 2018:1–11. doi: 10.1080/10406638.2018.1559208.
    1. Lippi G., Mattiuzzi C., Cervellin G. Meat consumption and cancer risk: a critical review of published meta-analyses. Crit. Rev. Oncol. 2016;97:1–14. doi: 10.1016/j.critrevonc.2015.11.008.
    1. Sun J.-W., Zhao L.-G., Yang Y., Ma X., Wang Y.-Y., Xiang Y.B. Obesity and Risk of Bladder Cancer: A Dose-Response Meta-Analysis of 15 Cohort Studies. PLoS ONE. 2015;10:e0119313. doi: 10.1371/journal.pone.0119313.
    1. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat. Rev. Cancer. 2012;12:159–169. doi: 10.1038/nrc3215.
    1. Singh N., Baby D., Rajguru J.P., Patil P.B., Thakkannavar S.S., Pujari V.B. Inflammation and cancer. Ann. Afr. Med. 2019;18:121–126. doi: 10.4103/aam.aam_56_18.
    1. Keimling M., Behrens G., Schmid D., Jochem C., Leitzmann M.F. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br. J. Cancer. 2014;110:1862–1870. doi: 10.1038/bjc.2014.77.
    1. Ross A.G., Inobaya M.T., Olveda R.M., Chau T.N., Olveda D.U. Prevention and control of schistosomiasis: A current perspective. Res. Rep. Trop. Med. 2014;2014:65–75. doi: 10.2147/RRTM.S44274.
    1. Rambau P., Chalya P.L., Jackson K. Schistosomiasis and urinary bladder cancer in North Western Tanzania: A retrospective review of 185 patients. Infect. Agents Cancer. 2013;8:19. doi: 10.1186/1750-9378-8-19.
    1. Kurahashi N., Inoue M., Liu Y., Iwasaki M., Sasazuki S., Sobue T., Tsugane S., for the JPHC Study Group Passive smoking and lung cancer in Japanese non-smoking women: A prospective study. Int. J. Cancer. 2007;122:653–657. doi: 10.1002/ijc.23116.
    1. Cumberbatch M.G., Cox A., Teare M.D., Catto J.W., Cumberbatch M.M.G.K., Catto M.J.W.F. Contemporary Occupational Carcinogen Exposure and Bladder Cancer. JAMA Oncol. 2015;1:1. doi: 10.1001/jamaoncol.2015.3209.
    1. Lotan Y., Goodman P.J., Youssef R.F., Svatek R.S., Shariat S.F., Tangen C.M., Thompson I.M., Klein E.A. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. J. Urol. 2012;187:2005–2010. doi: 10.1016/j.juro.2012.01.117.
    1. Inobaya M., Chau T.N., Ng S.-K., MacDougall C., Olveda R.M., Tallo V.L., Landicho J.M., Malacad C.M., Aligato M.F., Guevarra J.R., et al. Mass drug administration and the sustainable control of schistosomiasis: Community health workers are vital for global elimination efforts. Int. J. Infect. Dis. 2018;66:14–21. doi: 10.1016/j.ijid.2017.10.023.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere